1 / 36

Vancomycin

Vancomycin. Class: Glycopeptide antibiotic MOA: Inhibition of bacterial cell wall synthesis by binding D-ala-D-ala. Goodman & Gilman’s The Pharmacological Basis of Therapeutics – 11 th Ed. (2006). “Penicillin binding protein”. Peptidoglycan Synthesis. Vancomycin. IV, PO

havily
Download Presentation

Vancomycin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vancomycin • Class: Glycopeptide antibiotic • MOA: Inhibition of bacterial cell wall synthesis by binding D-ala-D-ala Goodman & Gilman’s The Pharmacological Basis of Therapeutics – 11th Ed. (2006)

  2. “Penicillin binding protein” Peptidoglycan Synthesis

  3. Vancomycin • IV, PO • Spectrum: Gram (+) • Drug of Choice • MRSA • Indications • IV: Serious methicillin-resistant Staphylococcal infections: pneumonia, endocarditis, osteomyelitis, SSSI • PO: pseudomembranous colitis (metronidazole preferred) • Staphylococcal infections in Penicillin allergic patients • NOTE: Do not use in non-Penicillin allergic patients. Vancomycin does not kill as rapidly as antistaphylococcal β-lactams, and may negatively impact clinical outcome • Unique Qualities • Monitor trough serum concentrations • Poor oral absorption • Adjust dose for renal impairment • ADRs • “Red Man” Syndrome • Ototoxicity • Nephrotoxicity w/ other nephrotoxic agents

  4. Vancomycin • Mechanism of action: Inhibits bacterial cell wall synthesis • Spectrum of action: Gram positive organisms • Including: Listeria, Rhodococcus, Peptostreptococcus • Bacteriostatic against enterococcus • Mechanism of resistance: • Enterococcus: Van A – E • Peptidoglycan precursor has decreased affinity for vancomycin – D-ala-D-ala replaced by D-ala-D-lac • Staphylococcus aureus: • VISA isolates: • Increased amount of precursor with decreased affinity • Thicker cell wall • hVISA: heterogenous bacterial population

  5. Vancomycin • Dose: • Based on total body weight and renal function • 15 – 20 mg/kg • Normal renal function: q 12 dosing • Goal trough concentrations: • 10 – 15 mcg/mL: bacteremia, skin and soft tissue infections • 15 – 20 mcg/mL: osteomyelitis, meningitis, pneumonia

  6. Linezolid • Class: Oxazolidinedione • MOA: Binds P site of 50s ribosomal subunit, preventing translation initiation Goodman & Gilman’s The Pharmacological Basis of Therapeutics – 11th Ed. (2006) http://www.chm.bris.ac.uk/motm/linezolid/linezolid.htm

  7. Linezolid • IV, PO • Gram (+) Indications • VRE (E. faecium) • Nosocomial pneumonia (S. aureus) • Community-acquired pneumonia (S. pneumoniae) • cSSSI (S. aureus) • Unique Qualities • F~100%, IV=PO • Reserve use for treatment of multiple drug resistant strains • No CYP interaction • ADRs • Generally well tolerated w/ minor SE in short term Rx • Myelosuppression: anemia, leukopenia, pancytopenia, thrombocytopenia • Peripheral and optic neuropathy

  8. Linezolid • Penetration: • Plasma • Pulmonary lining • Blister fluid • Dose (IV or PO): 600 mg Q12H • Drug-drug interactions: • Non-selective inhibitor of MAO • Possible serotonergic or adrenergic interaction with anti-depressant medications (incidence < 1%) > MIC90 for Staphylococcus

  9. Daptomycin • Class: Cyclic lipopeptide • MOA: In the presence of Ca2+, binds bacterial membrane resulting in depolarization Goodman & Gilman’s The Pharmacological Basis of Therapeutics – 11th Ed. (2006) http://cubicin.com/am_moa.htm

  10. Daptomycin • Indications: • Treatment of complicated SSTI’s caused by gram positive bacteria • Treatment of Staphylococcus bacteremia and right-sided endocarditis • Not used for treatment of pneumonia due to binding reaction with surfactant  inactivates daptomycin • MOA: • Binds membrane  Rapid depolarization  Cell death

  11. Daptomycin • Pharmacokinetic profile: • Concentration-dependent killing • Post-antibiotic effect • Available for intravenous use only • Penetration: • Good penetration into vascular tissues and plasma • Currently testing penetration into cerebral spinal fluid • Dose: • SSTIs: 4 mg/kg IV daily • Bacteremia: 6 mg/kg IV daily • Adjust for decreased renal function – CrCl < 30, use qod • Can Interact with certain assays for INR testing – results in falsely high INR  recommend point of care testing

  12. Macrolide Mechanism of Action • Bacteriostatic • Inhibits protein synthesis • Bind reversibly to 50s unit of the ribosome • Blocks translocation of peptides from A-site to P-site. Goodman and Gilman’s The Pharmacological Basic of Therapeutics. 11ed. 2006

  13. Macrolides • Achieve higher tissue than plasma concentrations • Penetrate into respiratory, tonsillar, and prostate tissues • Also penetrate into PMN leukocytes • Important for Atypicals like: Chlamydia and Legionella species • PD: Time the bacteria is exposed to therapeutic concentrations above the MIC best predicts efficacy – time dependent killing

  14. Clarithromycin • 14-membered lactone ring • Replace hydroxyl group at C-6 position with methoxyl group • Increase stability under acidic conditions • Partially metabolized via CPYP3A4 converted to active metabolite 14-OH-clarithromycin • Primarily excreted in urine Goodman and Gilman’s The Pharmacological Basic of Therapeutics. 11ed. 2006

  15. Clarithromycin • PO: Biaxin® 250-500 mg q 12 hours; Biaxin XL® 1000 mg qday • Spectrum of Activity: Gram (+) and Gram (-) • Indications: otitis media, CAP, pharyngitis/tonsillitis, sinusitis, uncomplicated skin infections, prevention of MAC, duodenal ulcer disease • S. aureus, S. pyogenes, S. pneumoniae, Mycobacterium avium complex • C. pneumoniae, C. trachomatis, L. pneumoniae • H. influenzae, H.pylori • Drug Interactions: Substrate of CYP 3A4 and Inhibits CPY 3A4(major) CYP 1A2 (weak) • Theophylline, statins, digoxin, warfarin, cyclosporine • Renal Adjustments: • CrCl < 30 ml/min: ½ the normal dose or double the dosing interval • ADR: • Prolongs the QT interval – use with caution in CAD • N/V, diarrhea, headache • Counseling Points: • Take XL formulation with food; do not chew or crush

  16. Azithromycin • 15-membered lactone ring • N-methyl group inserted between C-9 and C-10 • Ketone replaced with –CH2 Goodman and Gilman’s The Pharmacological Basic of Therapeutics. 11ed. 2006

  17. Azithromycin • PO, IV • Azithromyicn: 500 mg x day 1 then 250 mg x day 2-5 • STDs: C. trachomatis: 1 g x 1; N. gonorrheae: 2 g x 1 • Spectrum of Activity: Less Gram (+), increased Gram (-) • Indications: otitis media, pharyngitis/tonsillitis, upper and lower respiratory tract infections, skin and skin structure, CAP, PID, STDs • S. aureus, S. pneumoniae, H. influenzae, Mycobacterium avium complex • C. trachomatis, M. catarrhalis, M. pneumonia, N. gonorrheae, Chlamydia pneumoniae • Drug Interactions: not as significant as other macrolides • Most documented with cyclosporine and tacrolimus • Unique Characteristics: • T ½ 60-70 hours • Caution in patients with CrCl < 10 ml/min • ADRs: • Generally well-tolerated, may cause GI upset

  18. Macrolide Resistance • Decrease of permeation of drug through the cell membrane, or drug efflux pumps • Methylase modifies the ribosomal target • Hydrolysis of macrolides by endogenous esterase

  19. Clindamycin • Class: Lincosamide • Mechanism of Action: Binds exclusively to the 50S subunit of bacterial ribosomes and suppress protein synthesis

  20. Trade names: Cleocin ®, Clindesse®, Clindagel ®, Delivery forms: capsules: 75, 150, 300 mg; granules for oral solution 75mg/5ml; injection 150 mg/ml; vaginal cream 2%; vaginal suppositories 100 mg; Clindamax ®, Evoclin ® topical gel 1%; topical lotion 1%; topical solution 1%; foam 1% Clindamycin

  21. Indications: Serious infections caused by susceptible anaerobic bacteria Off-label indications: CNS toxoplasmosis in AIDS patients in addition to pyrimethamine; chlamydia infections in women; bacterial vaginosis due to Gardnerella vaginalis Dosing: Adults:150-450 mg Q 6 hrs Children:8-20 mg/kg/day divided TID-QID Instructions: Take with full glass of water Warning: Pseudomembranous colitis Clindamycin

  22. Precautions: Renal impairment/liver disease Elderly Meningitis GI disease Superinfections Pregnancy Category B Drug Interactions: Erythromycin Neuromuscular blocking agents ADRs: Dermatologic, GI, Hypersenstivity Clindamycin

  23. Aminoglycosides • Bactericidal inhibitors of protein synthesis • Concentration dependent bacteria killing • Postantibiotic effect • Major limitation of use is toxicity • Nephrotoxicity • Ototoxicity

  24. Aminoglycosides: Indications • Primarily against aerobic, gram negative bacilli • Activity against gram positive bacteria limited • Synergistic effect against “sensitive” (high-level) streptococci and enterococci when used with a cell wall active agent

  25. Penetrating the Cell Gram Negative Bacteria • Diffuse through porin proteins on the outer membrane of gram negative cell wall • Transport across inner membrane depends on electron transport • Membrane potential drives permeation • Transport can be blocked by reduction in pH and anaerobic environment Adapted from: http://web.indstate.edu/thcme/micro/respiratory/sld006.htm

  26. Mechanism of Action • Bactericidal • Inhibit protein synthesis • Bind to bacterial 30S ribosomal subunit • Blocks initiation of protein synthesis • Cause misreading of mRNA template • Cause premature termination of translocation Goodman and Gilman’s

  27. Aminoglycosides: Resistance Modes of resistance • Decreased permeation of aminoglycosides • Low affinity for bacterial ribosome • Drug inactivation by microbial enzymes • Important clinically • Amikacin is less vulnerable

  28. Structure Goodman and Gilman’s

  29. Aminoglycosides • Resistance: Intrinsic vs. Acquired • Intrinsic: • Anaerobes: lack active electron transport chain to cross membrane • Mutation at 16s rRNA (ie TB) • Acquired: • Efflux: seen in Pseudomonas • Decreased transmembrane potential: seen in Enterococcus

  30. Aminoglycosides • Distribution: • Freely into the vascular space • Interstitial spaces of most tissues • Volume of distribution increases in edematous states and decreases in obese patients (on L/kg basis) • Decreased concentrations: • Bronchial secretions, CSF, biliary tract, synovial fluid, and in the eye • Excreted by the kidneys • Half-life: 1.5 to 3.5 hours

  31. Aminoglycosides • Toxicity: • Nephrotoxicity: • Incidence 5% to 25% • Risk factors: • Ototoxicity (cochlear, vestibular) • Neuromuscular blockade (very rare)

  32. Toxicity • Dependent on: • Total amount of drug AND duration of therapy • Nephrotoxicity • Most often reversible • Accumulation of drug in proximal tubular cells • Mild rise in Scr (0.5-1 mg/dl) • Reduced excretion of drug = increased risk of ototoxicity • Ototoxicity • Largely irreversible if not caught early • Destruction of vestibular and cochlear sensory cells • High-pitched tinnitus is often 1st symptom

  33. Aminoglycosides • Site of infection: determines goal levels and dose • Peak concentrations: • Gram + Synergy: 3 – 5 mcg/mL • UTI: 3 – 4 mcg/mL • Bacteremia: 6 – 8 mcg/mL • Pneumonia: 8 – 10 mcg/mL • Weight based dosing: use IBW or ABW • Interval: once-daily dosing for gram-negative infection (normal renal function, 7 mg/kg/day). Gram + synergy 1mg/kg q 8-12h.

  34. Gentamicin: Once Daily Dosing • 5-7mg/kg/24hrs (ABW) • Target peak 14-20 mcg/ml • Allows low troughs • Avoid in patients with: • Burns, CF, pregnancy, children, endocarditis or CrCl < 20ml/min

  35. Tobramycin • Antimicrobial activity and PK properties very similar to gentamicin • Superior activity against P. aeruginosa • Less active than gentamicin against enterococci • Can be given IV or IM • Dosage and serum levels are same as gentamicin

  36. Amikacin • Broadest spectrum of activity • Resistant to aminoglycoside-inactivating enzymes • Less active against enterococci • Similar dosing interval and monitoring • Peak • Life-threatening infection 25-30 mcg/ml • Serious infection 20-25 mcg/ml • Trough • Life threatening infection 4-8 mcg/ml • Most infections 1-4 mcg/ml

More Related